ORLNC1 Suppresses Cell Growth in HER2-Positive Breast Cancer via miRNA-296 Sponging

被引:0
作者
Cheng, Xueyuan [1 ]
Huang, Zhong [1 ]
Pan, Anchao [2 ]
Long, Di [2 ,3 ]
机构
[1] Beihai Peoples Hosp, Dept Gen Surg, Beihai 536000, Guangxi, Peoples R China
[2] Guangxi Med Univ, Dept Gastrointestinal Surg, Wuming Hosp, Nanning 530199, Guangxi, Peoples R China
[3] Guangxi Med Univ, Dept Gastrointestinal Surg, Wuming Hosp, 26 Yongning Rd, Nanning 530199, Guangxi Zhuang, Peoples R China
关键词
lncRNAs; ORLNC1; miR-296; PTEN; HER2+breast cancer; RNAs; LONG NONCODING RNAS; HER2 AMPLICON INCLUDES; RESISTANCE; MICRORNAS; SURVIVAL; THERAPY;
D O I
10.2174/1566524022666220603113550
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Background: Accumulating research has demonstrated that aberrant levels of long noncoding RNAs (LncRNAs) are related to cancer progression. The effects of ORLNC1 in HER2+ breast cancer have yet to be explored. Methods: Real-time PCR was used to examine the expression of LncRNA ORLNC1 in HER+ breast cancer. CCK-8, wound healing and cell invasion assays were used to examine the effect of LncRNA ORLNC1 on HER+ breast cancer cells. Luciferase reporter assay was utilized to determine the regulatory relationship between LncRNA ORLNC1 and miR-296. Western blotting was used to measure the expression of PTEN. Xenograft mouse model was used to examine the effect of LncRNA ORLNC1 on tumor progression in vivo. Results: In this study, our findings revealed downregulation of ORLNC1 in HER2+ breast cancer specimens and cell lines. Low levels of ORLNC1 were related to poor prognosis and advanced cancer stage. Using gain- and loss-of-function assays, the ability of these tumor cells to proliferate was found to be inhibited by ORLNC1 in vitro and in vivo. Further analyses revealed that miR-296/PTEN axis is directly targeted by ORLNC1. Consequently, over-expression of miR-296 efficiently abrogated the up-regulation of PTEN induced by ORLNC1, suggesting that ORLNC1 positively regulates PTEN expression by competitively binding to miR-296. Conclusion: Our results indicate that lncRNA ORLNC1 acts as a tumor suppressor by regulating the miR-296/PTEN axis in HER2+ breast cancer.
引用
收藏
页码:289 / 299
页数:11
相关论文
共 50 条
[1]  
Asif Hafiz Muhammad, 2016, Asian Pac J Cancer Prev, V17, P1609
[2]   Overview of Breast Cancer and Implications of Overtreatment of Early-Stage Breast Cancer: An Indian Perspective [J].
Bhattacharyya, Gouri Shankar ;
Doval, Dinesh C. ;
Desai, Chirag J. ;
Chaturvedi, Harit ;
Sharma, Sanjay ;
Somashekhar, S. P. .
JCO GLOBAL ONCOLOGY, 2020, 6 :789-798
[3]   Hsa_circ_0000515 is a novel circular RNA implicated in the development of breast cancer through its regulation of the microRNA-296-5p/CXCL10 axis [J].
Cai, Fenglin ;
Fu, Wenjie ;
Tang, Lei ;
Tang, Jinhai ;
Sun, Jinming ;
Fu, Guangshun ;
Ye, Gang .
FEBS JOURNAL, 2021, 288 (03) :861-883
[4]   HER Targeting in HER2-Negative Breast Cancers: Looking for the HER3 Positive [J].
Campbell, Marcia R. ;
Moasser, Mark M. .
CLINICAL CANCER RESEARCH, 2015, 21 (13) :2886-2888
[5]   Cancer LncRNA Census reveals evidence for deep functional conservation of long noncoding RNAs in tumorigenesis [J].
Carlevaro-Fita, Joana ;
Lanzos, Andres ;
Feuerbach, Lars ;
Hong, Chen ;
Mas-Ponte, David ;
Pedersen, Jakob Skou ;
Johnson, Rory ;
Abascal, Federico ;
Amin, Samirkumar B. ;
Bader, Gary D. ;
Barenboim, Jonathan ;
Beroukhim, Rameen ;
Bertl, Johanna ;
Boroevich, Keith A. ;
Brunak, Soren ;
Campbell, Peter J. ;
Carlevaro-Fita, Joana ;
Chakravarty, Dimple ;
Chan, Calvin Wing Yiu ;
Chen, Ken ;
Choi, Jung Kyoon ;
Deu-Pons, Jordi ;
Dhingra, Priyanka ;
Diamanti, Klev ;
Feuerbach, Lars ;
Fink, J. Lynn ;
Fonseca, Nuno A. ;
Frigola, Joan ;
Gambacorti-Passerini, Carlo ;
Garsed, Dale W. ;
Gerstein, Mark ;
Getz, Gad ;
Gonzalez-Perez, Abel ;
Guo, Qianyun ;
Gut, Ivo G. ;
Haan, David ;
Hamilton, Mark P. ;
Haradhvala, Nicholas J. ;
Harmanci, Arif O. ;
Helmy, Mohamed ;
Herrmann, Carl ;
Hess, Julian M. ;
Hobolth, Asger ;
Hodzic, Ermin ;
Hong, Chen ;
Hornshoj, Henrik ;
Isaev, Keren ;
Izarzugaza, Jose M. G. ;
Johnson, Todd A. ;
Juul, Malene .
COMMUNICATIONS BIOLOGY, 2020, 3 (01)
[6]   The PT N/PI3K/AKT pathway in vivo, cancer mouse models [J].
Carnero, Amancio ;
Paramio, Jesus M. .
FRONTIERS IN ONCOLOGY, 2014, 4
[7]   A lncRNA landscape in breast cancer reveals a potential role for AC009283.1 in proliferation and apoptosis in HER2-enriched subtype [J].
Cedro-Tanda, Alberto ;
Rios-Romero, Magdalena ;
Romero-Cordoba, Sandra ;
Cisneros-Villanueva, Mireya ;
Gloria Rebollar-Vega, Rosa ;
Alberto Alfaro-Ruiz, Luis ;
Jimenez-Morales, Silvia ;
Dominguez-Reyes, Carlos ;
Villegas-Carlos, Felipe ;
Tenorio-Torres, Alberto ;
Bautista-Pina, Veronica ;
Omar Beltran-Anaya, Fredy ;
Hidalgo-Miranda, Alfredo .
SCIENTIFIC REPORTS, 2020, 10 (01)
[8]   PTEN: Tumor Suppressor and Metabolic Regulator [J].
Chen, Chien-Yu ;
Chen, Jingyu ;
He, Lina ;
Stiles, Bangyan L. .
FRONTIERS IN ENDOCRINOLOGY, 2018, 9
[9]   Clinical development of immunotherapies for HER2+ breast cancer: a review of HER2-directed monoclonal antibodies and beyond [J].
Costa, Ricardo L. B. ;
Czerniecki, Brian J. .
NPJ BREAST CANCER, 2020, 6 (01)
[10]   Disruption of Long Noncoding RNAs Targets Cancer Hallmark Pathways in Lung Tumorigenesis [J].
Davalos, Veronica ;
Esteller, Manel .
CANCER RESEARCH, 2019, 79 (12) :3028-3030